Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), as one of the most promising targeted drug for new cancer therapeutics, is limited in clinical application by the evolution of resistance in many cancer cell lines, especially in malignant melanoma. Thus, it is urgently needed to ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Wenqiang, Li, Xiaoling, Zheng, Shanyuan, Zheng, Wenjie, Wong, Yum-shing, Chen, Tianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202134/
https://www.ncbi.nlm.nih.gov/pubmed/25277183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202134/
https://www.ncbi.nlm.nih.gov/pubmed/25277183

Ejemplares similares